|1.||Chen, Ching-Shih: 5 articles (11/2015 - 05/2006)|
|2.||Fonseca, Vivian: 5 articles (06/2015 - 01/2002)|
|3.||Buchanan, Thomas A: 5 articles (07/2006 - 06/2004)|
|4.||Abbasi, Fahim: 4 articles (09/2015 - 02/2005)|
|5.||Reaven, Gerald M: 4 articles (09/2015 - 02/2005)|
|6.||Schwartz, Gregory G: 4 articles (12/2014 - 05/2003)|
|7.||Zinman, B: 4 articles (01/2013 - 09/2006)|
|8.||Nesto, Richard W: 4 articles (03/2010 - 12/2003)|
|9.||Xiang, Anny H: 4 articles (02/2006 - 06/2004)|
|10.||Marroquin, Aura: 4 articles (02/2006 - 06/2004)|
11/17/2001 - "They could also prove effective in combination with a thiazolidinedione, a drug class that targets insulin resistance. "
06/01/2007 - "Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance?"
10/01/1998 - "A hyperinsulinaemic euglycaemic clamp study in Zucker fatty rats showed an amelioration of whole-body insulin resistance by the T-174 treatment. "
07/06/2012 - "Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione."
05/01/2010 - "Thiazolidinedione (TZD) and biguanide counter insulin resistance, but act by different mechanisms. "
|2.||Type 2 Diabetes Mellitus (MODY)
11/01/2014 - "The thiazolidinedione (TZDs) class of drugs are very effective for the treatment of type 2 diabetes mellitus (T2DM). "
06/01/2013 - "The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus."
04/01/2013 - "A review on the development in the field of NIDDM based thiazolidinedione PPARγ agonists."
04/01/2012 - "The process of updating a systematic review and meta-analysis of thiazolidinedione-related fractures in patients with type 2 diabetes mellitus was used as a case study. "
02/01/2010 - "Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus."
01/01/2015 - "As full agonists of PPARγ, thiazolidinedione (TZD) drugs elicit antidiabetic effects by targeting PPARγ but is accompanied by weight gain, fluid retention and cardiovascular risk associated with their transcriptional agonism potency. "
01/01/2009 - "Weight gain following thiazolidinedione therapy is predicted to result from both reduced UGE and non-UGE-dependent mechanisms. "
02/01/2008 - "This combination offers advantages when compared to others currently used, particularly if one considers the more stringent guidelines with a higher risk of hypoglycaemic events in patient receiving sulfonylureas and mild hyperglycaemia or weight gain with thiazolidinedione (TZD). "
11/01/2011 - "DPP-4 inhibitors have neutral effect on body weight but their combination with a thiazolidinedione (TZD) results in slight weight gain averaging 0.5 to 1.3 kg compared with placebo. "
02/01/2011 - "Patients treated with a sulphonylurea are at increased risk for hypoglycaemia and moderate weight gain, whereas those receiving a thiazolidinedione are subject to an increased risk of weight gain, oedema, heart failure or fracture. "
07/01/2000 - "Our findings suggest that the thiazolidinedione group had an antithrombotic effect and was beneficial in preventing vascular complications often observed in diabetes mellitus."
05/01/2011 - "Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus."
08/01/2009 - "To determine if patients with diabetes mellitus taking a thiazolidinedione experienced higher proportions of distal upper and lower limb fractures compared with those not taking a thiazolidinedione, as recent US Food and Drug Administration safety alerts suggested. "
12/01/2008 - "Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus."
02/01/2000 - "These favorable effects suggest the thiazolidinedione may have inhibitory actions on both macroangiopathy and microangiopathy in patients with diabetes mellitus. "
01/01/2008 - "Most importantly, we emphasize the apparent lack of any long-term mortality consequences and a relative improvement in outcomes associated with thiazolidinedione-induced 'heart failure' and discuss the potential mechanisms underlying this apparent paradox. "
07/03/2007 - "This study sought to examine the relationship between thiazolidinedione (TZD) use and outcomes in ambulatory patients with diabetes and heart failure (HF). "
10/01/2005 - "This study showed a likely association between thiazolidinedione therapy and hospitalization for heart failure within 60 days of the prescription date. "
04/01/2011 - "Thiazolidinedione use in elderly patients with type 2 diabetes: with and without heart failure."
05/01/2010 - "Despite many potential benefits, thiazolidinedione (TZD) use has been associated with increased exacerbation rate of heart failure due to fluid retention. "
|6.||Peroxisome Proliferator-Activated Receptors (PPAR)